BCL-XL blockage in TNBC models confers vulnerability to inhibition of specific cell cycle regulators.


Journal

Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395

Informations de publication

Date de publication:
2021
Historique:
received: 16 03 2021
accepted: 23 08 2021
entrez: 14 10 2021
pubmed: 15 10 2021
medline: 8 2 2022
Statut: epublish

Résumé

Cell cycle regulators are frequently altered in Triple-Negative Breast Cancer (TNBC). Emerging agents targeting these signals offer the possibility to design new combinatorial therapies. However, preclinical models that recapitulate TNBC primary resistance and heterogeneity are essential to evaluate the potency of these combined treatments.

Identifiants

pubmed: 34646365
doi: 10.7150/thno.60503
pii: thnov11p9180
pmc: PMC8490507
doi:

Substances chimiques

BCL2L1 protein, human 0
Cell Cycle Proteins 0
bcl-X Protein 0
Cyclin-Dependent Kinases EC 2.7.11.22

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

9180-9197

Informations de copyright

© The author(s).

Déclaration de conflit d'intérêts

Competing Interests: The authors have declared that no competing interest exists.

Références

Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Oncogene. 2006 Apr 20;25(17):2468-76
pubmed: 16331257
Cancer Res. 2011 Jul 1;71(13):4329-33
pubmed: 21712406
Nat Commun. 2018 Aug 8;9(1):3164
pubmed: 30089774
Nat Rev Cancer. 2017 Jan 27;17(2):93-115
pubmed: 28127048
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Mol Cancer Ther. 2006 Nov;5(11):2644-58
pubmed: 17121911
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Tumour Biol. 2014 Mar;35(3):1847-54
pubmed: 24096545
Cancer Discov. 2019 Feb;9(2):176-198
pubmed: 30679171
Nat Rev Dis Primers. 2019 Sep 23;5(1):66
pubmed: 31548545
Mol Cell. 2020 Oct 15;80(2):183-192
pubmed: 32946743
Int J Oncol. 2019 Jan;54(1):87-97
pubmed: 30365046
J Cell Mol Med. 2019 Sep;23(9):6442-6453
pubmed: 31359594
Mol Cell. 2020 May 7;78(3):459-476.e13
pubmed: 32240602
Mol Cancer. 2018 Jul 25;17(1):104
pubmed: 30045773
J Cancer. 2021 Jan 1;12(3):740-753
pubmed: 33403032
Genome Biol. 2014;15(12):550
pubmed: 25516281
Biochim Biophys Acta. 2012 Jan;1819(1):28-37
pubmed: 21978825
Oncogene. 2006 Aug 28;25(38):5220-7
pubmed: 16936740
Bioinformatics. 2017 Aug 01;33(15):2413-2415
pubmed: 28379339
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Oncogene. 2007 Aug 30;26(40):5851-65
pubmed: 17369848
Cancers (Basel). 2018 Dec 19;10(12):
pubmed: 30572639
J Biol Chem. 2019 Jan 18;294(3):875-886
pubmed: 30482844
PLoS Biol. 2021 Jan 4;19(1):e3001029
pubmed: 33395410
Adv Sci (Weinh). 2020 Dec 16;8(3):2003049
pubmed: 33552868
Nat Commun. 2020 May 11;11(1):2350
pubmed: 32393766
Cancers (Basel). 2020 Sep 19;12(9):
pubmed: 32961773
Oncogene. 2002 Nov 7;21(51):7765-75
pubmed: 12420213
PLoS One. 2017 Dec 20;12(12):e0189007
pubmed: 29261702
Ther Adv Med Oncol. 2017 Feb;9(2):83-105
pubmed: 28203301
Mol Cell. 2020 Nov 19;80(4):682-698.e7
pubmed: 33152268
Cancer Cell Int. 2020 Oct 12;20:501
pubmed: 33061853
Breast Cancer Res Treat. 2019 Apr;174(3):615-625
pubmed: 30607633
Pharmacogenomics. 2017 Nov;18(17):1595-1609
pubmed: 29095114
Cancer Discov. 2014 Feb;4(2):232-45
pubmed: 24356096
Clin Cancer Res. 2017 Sep 15;23(18):5561-5572
pubmed: 28606920
Sci Rep. 2019 Sep 10;9(1):13014
pubmed: 31506466
Biochem Soc Trans. 2020 Apr 29;48(2):657-665
pubmed: 32311020
Cell. 2007 Sep 21;130(6):986-8
pubmed: 17889643

Auteurs

Olivier Castellanet (O)

Aix Marseille Univ, CNRS, Developmental Biology Institute of Marseille (IBDM), Turing Center for Living Systems, Parc Scientifique de Luminy, Marseille (France).

Fahmida Ahmad (F)

Aix Marseille Univ, CNRS, Developmental Biology Institute of Marseille (IBDM), Turing Center for Living Systems, Parc Scientifique de Luminy, Marseille (France).

Yaron Vinik (Y)

Weizmann Institute of Science, Department of Molecular Cell Biology, Rehovot (Israel).

Gordon B Mills (GB)

Knight Cancer Institute, Portland, OR 97201, USA.

Bianca Habermann (B)

Aix Marseille Univ, CNRS, Developmental Biology Institute of Marseille (IBDM), Turing Center for Living Systems, Parc Scientifique de Luminy, Marseille (France).

Jean-Paul Borg (JP)

Aix Marseille Univ, Centre de Recherche en Cancérologie de Marseille (CRCM), Equipe labellisée Ligue 'Cell polarity, cell signaling and cancer', Inserm, CNRS, Institut Paoli-Calmettes, Marseille (France).
Institut Universitaire de France (IUF).

Sima Lev (S)

Weizmann Institute of Science, Department of Molecular Cell Biology, Rehovot (Israel).

Fabienne Lamballe (F)

Aix Marseille Univ, CNRS, Developmental Biology Institute of Marseille (IBDM), Turing Center for Living Systems, Parc Scientifique de Luminy, Marseille (France).

Flavio Maina (F)

Aix Marseille Univ, CNRS, Developmental Biology Institute of Marseille (IBDM), Turing Center for Living Systems, Parc Scientifique de Luminy, Marseille (France).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH